A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Stemline Therapeutics

Protocol Number
STML-401-0214

To Learn More Call
201-510-0910